BR112022021065A2 - Anticorpos terapêuticos de musk - Google Patents

Anticorpos terapêuticos de musk

Info

Publication number
BR112022021065A2
BR112022021065A2 BR112022021065A BR112022021065A BR112022021065A2 BR 112022021065 A2 BR112022021065 A2 BR 112022021065A2 BR 112022021065 A BR112022021065 A BR 112022021065A BR 112022021065 A BR112022021065 A BR 112022021065A BR 112022021065 A2 BR112022021065 A2 BR 112022021065A2
Authority
BR
Brazil
Prior art keywords
musk
antibodies
therapeutic
present
musk antibodies
Prior art date
Application number
BR112022021065A
Other languages
English (en)
Portuguese (pt)
Inventor
J Burden Steven
Koide Shohei
Koide Akiko
LELOUP Nadia
OURY Julien
Silence Karen
VANHAUWAERT Roeland
Blanchetot Christophe
Original Assignee
Univ New York
Argenx Iip Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York, Argenx Iip Bv filed Critical Univ New York
Publication of BR112022021065A2 publication Critical patent/BR112022021065A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112022021065A 2020-04-17 2021-04-16 Anticorpos terapêuticos de musk BR112022021065A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063011986P 2020-04-17 2020-04-17
US202063038633P 2020-06-12 2020-06-12
US202063112375P 2020-11-11 2020-11-11
PCT/US2021/027801 WO2021212053A2 (en) 2020-04-17 2021-04-16 Therapeutic musk antibodies

Publications (1)

Publication Number Publication Date
BR112022021065A2 true BR112022021065A2 (pt) 2023-02-23

Family

ID=75850676

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022021065A BR112022021065A2 (pt) 2020-04-17 2021-04-16 Anticorpos terapêuticos de musk

Country Status (12)

Country Link
US (2) US11492401B2 (https=)
EP (1) EP4136115A2 (https=)
JP (2) JP7772715B2 (https=)
KR (1) KR20230028217A (https=)
CN (1) CN115843268A (https=)
AU (1) AU2021256049A1 (https=)
BR (1) BR112022021065A2 (https=)
CA (1) CA3175597A1 (https=)
IL (1) IL297295A (https=)
MX (1) MX2022011856A (https=)
PH (1) PH12022552483A1 (https=)
WO (1) WO2021212053A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023147489A2 (en) * 2022-01-28 2023-08-03 argenx BV Anti-musk antibodies for use in treating neuromuscular disorders
WO2023218099A1 (en) * 2022-05-13 2023-11-16 argenx BV In utero treatment of a fetus having genetic disease/neuromuscular disease
AU2024271522A1 (en) * 2023-05-15 2025-11-20 argenx BV Antibodies for use in agrin-deficient disorders
WO2025129132A1 (en) * 2023-12-14 2025-06-19 Invenra Inc. Multispecific binding agents that target ctla4 and/or cd25 and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5814478A (en) 1995-12-15 1998-09-29 Regeneron Pharmaceuticals, Inc. Tyrosine kinase receptors and ligands
US6737249B1 (en) 1997-08-22 2004-05-18 Genentech, Inc. Agonist antibodies
US6624819B1 (en) 2000-05-01 2003-09-23 Broadcom Corporation Method and system for providing a flexible and efficient processor for use in a graphics processing system
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
CA2453822C (en) 2001-08-03 2011-02-22 Tyco Healthcare Group Lp Tissue marking apparatus and method
US6921538B2 (en) 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
JP5932670B2 (ja) * 2010-03-11 2016-06-08 ライナット ニューロサイエンス コーポレイション ｐＨ依存性の抗原結合を有する抗体
JP2011207769A (ja) 2010-03-29 2011-10-20 Arubion:Kk 化粧料及び皮膚外用剤
WO2013074636A1 (en) 2011-11-14 2013-05-23 New York University Muscle specific receptor kinase and modulation thereof
US9574015B2 (en) 2013-09-13 2017-02-21 New York University Methods for treating muscle specific receptor kinase (MuSK) myasthenia gravis with the Ig1 domain of MuSK

Also Published As

Publication number Publication date
AU2021256049A1 (en) 2022-11-03
JP2026056615A (ja) 2026-04-01
IL297295A (en) 2022-12-01
PH12022552483A1 (en) 2024-02-05
JP7772715B2 (ja) 2025-11-18
US11492401B2 (en) 2022-11-08
US20220259304A1 (en) 2022-08-18
WO2021212053A3 (en) 2021-11-18
WO2021212053A8 (en) 2022-09-29
MX2022011856A (es) 2023-02-23
CN115843268A (zh) 2023-03-24
WO2021212053A2 (en) 2021-10-21
JP2023522212A (ja) 2023-05-29
CA3175597A1 (en) 2021-10-21
KR20230028217A (ko) 2023-02-28
US20230151091A1 (en) 2023-05-18
EP4136115A2 (en) 2023-02-22

Similar Documents

Publication Publication Date Title
BR112022021065A2 (pt) Anticorpos terapêuticos de musk
BRPI0821658B8 (pt) anticorpo monoclonal humano ou um fragmento de ligação ao antígeno do mesmo que se liga a hnkg2d e seus usos
BR112019010265A2 (pt) anticorpos anti_cd137 inovadores e usos dos mesmos
BR112021014074A2 (pt) Proteínas de ligação ao antígeno anti-receptor il2 gama
BR112019005670A2 (pt) anticorpos anti-muc16 (mucina 16)
BR112022019531A2 (pt) Molécula biespecífica de ligação ao antígeno, ácido nucleico isolado, vetor de expressão, célula hospedeira, métodos para produzir uma molécula biespecífica de ligação ao antígeno e para tratar um indivíduo com câncer, composição farmacêutica e uso da molécula biespecífica
EA201990781A9 (ru) Анти-steap2 антитела, конъюгаты антитело-лекарственное средство и биспецифические антигенсвязывающие молекулы, которые связывают steap2 и cd3, и их применение
BR112021016398A2 (pt) Anticorpos cd33 e métodos de uso dos mesmos para tratar o câncer
BR112019000436A2 (pt) anticorpos anti-pd-1, método de produção e método de uso dos mesmos
BR112022000216A2 (pt) Anticorpos direcionados a dll3 e usos dos mesmos
BR112022016232A2 (pt) Proteínas biespecíficas anti-her2 manipuladas
BR112016016207A2 (pt) Anticorpo anti-pd-l1 isolado ou fragmento de ligação ao antígeno do mesmo, seu método de produção, composição farmacêutica, molécula de polinucleotídeo isolada, vetor, célula, e uso dos mesmos
BR112022003635A2 (pt) Anticorpo anti-vsig4 ou fragmento de ligação ao antígeno e seu uso
BRPI0808940B8 (pt) anticorpo humano-murino quimérico ou xegogeneico, humanizado, humano ou seu fragmento de ligação, vetor de expressão, microrganismo transgênico, método para preparar um anticorpo ou um fragmento de ligação, composição, composição de diagnóstico, uso do anticorpo ou fragmento de ligação, kit para o diagnóstico de um tumor e uso da molécula de antígeno ligante ao tumor
BR112022011037A2 (pt) Anticorpos ddr1 novos e usos dos mesmos
JOP20210166A1 (ar) علاج الصداع الناتج عن فرط استعمال الأدوية باستخدام أجسام مضادة لـcgrp أو أجسام مضادة لـcgrp-r
MX2020006171A (es) Terapia de combinacion con anticuerpos anti interleucina-8 (il-8) y anticuerpos anti receptor de muerte programada (pd-1) para tratar cancer.
MY206214A (en) Monoclonal antibodies that bind specifically to human trbv9
EA202191666A1 (ru) Антитела к il-27 и их применение
BR112023002455A2 (pt) Anticorpos fgfr3 e métodos de uso
MX2023014069A (es) Composiciones y métodos para el tratamiento del cáncer de próstata.
BR112023023558A2 (pt) Anticorpos anti-tmprss6 e usos dos mesmos
BR112022026999A2 (pt) Anticorpos anti-il-36r para tratamento de dermatoses neutrofílicas
BR112022020232A2 (pt) Anticorpos contra nkp46 e construtos dos mesmos para o tratamento de cânceres e infecções
BR112022022986A2 (pt) Anticorpos anti-hemojuvelina (hjv) para tratar mielofibrose

Legal Events

Date Code Title Description
B25F Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement

Owner name: NEW YORK UNIVERSITY (US) ; ARGENX IIP BV (BE)

Free format text: A FIM DE ATENDER A ALTERACAO DE NOME REQUERIDA ATRAVES DA PETICAO 870230041244 DE 17/05/2023, E NECESSARIO ESCLARECER A DIVERGENCIA ENTRE O NOME DO DEPOSITANTE CONSTANTE NOS DOCUMENTOS APRESENTADOS ?ARGENX BENELUX? E O CONSTANTE NO FORMULARIO ?ARGENX BENELUX BV?.

B25D Requested change of name of applicant approved

Owner name: NEW YORK UNIVERSITY (US) ; ARGENX BENELUX BV (BE)

B25A Requested transfer of rights approved

Owner name: NEW YORK UNIVERSITY (US) ; ARGENX BV (BE)